WO2025056011 - PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PD-1 ANTIBODY AND SECOND ANTIBODY
National phase entry is expected:
Publication Number
WO/2025/056011
Publication Date
20.03.2025
International Application No.
PCT/CN2024/118665
International Filing Date
13.09.2024
Title **
[English]
PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PD-1 ANTIBODY AND SECOND ANTIBODY
[French]
COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTICORPS ANTI-PD-1 ET UN SECOND ANTICORPS
[Chinese]
包含抗PD-1抗体和第二抗体的药物组合物
Applicants **
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
CHIA TAI TIANQING PHARMACEUTICAL (GUANGZHOU), CO., LTD.
Inventors
KONG, Lingjie
LI, Yingchun
CHENG, Yanju
JIAO, Mengying
LIU, Chengjun
Priority Data
202311181084.9
13.09.2023
CN
202410962244.1
17.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1931 | |
| EPO | Filing, Examination, Granting | 12283 | |
| Japan | Filing, Examination, Granting | 2171 | |
| South Korea | Filing, Examination, Granting | 2140 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,265
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided is a pharmaceutical composition comprising an anti-PD-1 antibody and a second antibody. The second antibody is an anti-LAG-3 antibody. In addition, further provided are a preparation method for the pharmaceutical composition and a use of the pharmaceutical composition in preparation of a drug for treating diseases of a subject.[French]
L'invention concerne une composition pharmaceutique comprenant un anticorps anti-PD-1 et un second anticorps. Le second anticorps est un anticorps anti-LAG-3. L'invention concerne en outre un procédé de préparation de la composition pharmaceutique et une utilisation de la composition pharmaceutique dans la préparation d'un médicament pour le traitement de maladies d'un sujet.[Chinese]
提供一种包含抗PD-1抗体和第二抗体的药物组合物，其中，所述第二抗体为抗LAG-3抗体。此外，还提供所述药物组合物的制备方法以及所述药物组合物在制备用于治疗受试者疾病的药物中的用途。